Mentions
Extended reach
Total likes
Video views
AI synopsis
The social discussions emphasize tirzepatide's remarkable performance over semaglutide, with phrases like 'superior weight loss' and detailed statistics such as '-20.2% body weight' and '64.6% ≥15% weight loss,' which demonstrate deep engagement and a belief in its significant clinical impact. The tone and choice of words convey excitement about advancing obesity treatments based on solid research findings.
Most discussions fully support the study’s findings, highlighting tirzepatide’s superior weight loss results.
The posts show high curiosity and focus on detailed outcomes, indicating strong interest in the topic.
Many posts reference specific data, trials, and implications, demonstrating deep engagement with the research.
The emphasis on the novel evidence and potential clinical applications suggests high perceived impact on obesity treatment.
Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/mDYfCO3Bqy Editorial: Semaglutide and Tirzepatide to Treat Obesity https://t.co/2lenpsGjiI #Endocrinology https://t.co/wu0bFnRiYJ
Just published @nejm.org A randomized trial of Semaglutide (Ozempic) vs Tirzepatide (Mounjaro, Zepbound) at max doses demonstrates superiority of the latter for weight loss www.nejm.org/doi/full/10.1056/NEJMoa2416394
In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference. Full trial results and Research Summary: https://t.co/mDYfCO3Bqy https://t.co/17HHbfakBJ
สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
New in the July 3, 2025, issue of NEJM: Exercise after Chemotherapy for Colon Cancer (CHALLENGE phase 3 trial) https://t.co/uz69rdc01o Tirzepatide vs. Semaglutide for Obesity (SURMOUNT-5 phase 3b trial) https://t.co/mDYfCO3Bqy Pembrolizumab in Head and Neck Cancer https://t.co/ptsxD9hQiy
New #Obesity Publication → Head-to-Head Study Comparing Dual and Single Incretin Receptor Agonists in Obesity Treatment Click here to read the full study: https://t.co/o79sPe1CUW #obesityresearch #obesitymedicine
Peptides are gaining popularity with claims of fat loss, muscle growth, and healing. This video explains the most talked-about peptides, their research-backed benefits, risks, and the importance of FDA approval…
This video compares the results of a 2025 NEJM study on Ozempic and Mounjaro. Discover which medication showed greater weight loss, better glycemic control, and how their side effects compare, focusing on obesity and…
This week's podcast discusses BedMed trial findings, timing of BP meds, and related research on antihypertensive strategies, including concerns about bedtime dosing and associated risks, focusing on recent trials and…
Finally, a direct comparison of tirzepatide and semaglutide’s efficacy in obesity management. Tirzepatide showed greater weight loss and waist circumference reduction over 72 weeks, with manageable side effects. Both…
Listener feedback on nonculprit PCI in STEMI and major cardiac findings in hemodialysis patients. Key studies include the PISCES, REDUCE-IT, and STRENGTH trials, highlighting recent developments in acute MI management…
Join our scientific team discussing the most impactful papers of the month, including the comparison of Tirzepatide and Semaglutide for obesity, highlighting Tirzepatide's superior weight loss results and safety profile.
@Victor544222181 https://t.co/uOQhZcDW1r https://t.co/VqtCyZgNCy
RT @ValleAlfonso:
RT @EricTopol: Just published @NEJM A randomized trial of Semaglutide (Ozempic) vs Tirzepatide (Mounjaro, Zepbound) at max doses demonstra…
https://t.co/9To0dZzwA0
RT @EricTopol: Just published @NEJM A randomized trial of Semaglutide (Ozempic) vs Tirzepatide (Mounjaro, Zepbound) at max doses demonstra…
RT @cardio_tu: 2 min cardiology（臨床、担当：渡辺顕） Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Louis J Aronne et al. N…
2 min cardiology（臨床、担当：渡辺顕） Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Louis J Aronne et al. NEJM 2025; 393: 26-36. https://t.co/p6O1Xa6Bim →
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/Cc6XARLQaD
New NEJM study: Tirzepatide (10 mg, 15 mg) vs. Semaglutide (1.7 mg, 2.4 mg) for obesity in adults without diabetes. Which works best? PMID:40353578, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2416394 #Medsky #Pharmsky #RNA #ASHG #ESHG
New NEJM study: Tirzepatide (10 mg, 15 mg) vs. Semaglutide (1.7 mg, 2.4 mg) for obesity in adults without diabetes. Which works best? PMID:40353578, N Engl J Med 2025, @NEJM https://t.co/nhfXh50uMc #AI #Pharma #BioMed #RNA #ASHG #ESHG
6/ Beyond price, how do Wegovy & Zepbound compare? A New England Journal of Medicine @NEJM study tested them head-to-head. https://t.co/bEb7dR1rpH Over 72 weeks, patients on Zepbound lost ~20% of body weight vs ~14% on Wegovy.
دراسة طبية تقول ان #المونجارو ينزل الوزن اكثر من #اوزمبيك. للتفاصيل : Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/D63uxj5XDW
@KrisPatel99 latest findings from the SURMOUNT 5 trial. It's not even close.. Semaglutide is open to massive levels of compounding which eat into novos margins. I'm not allowed to buy either stocks due to conflicts of interest but if I could there is a clear winner https://t.co/THwuHpxeQX
RT @ValleAlfonso:
RT @ValleAlfonso:
Tirzepatida comparada con semaglutida para el tratamiento de la obesidad https://t.co/s1ROzBr76F PMID 40353578
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/8kFNQ5d8kC
Among participants with #obesity but without #diabetes, #treatment with #tirzepatide was superior to treatment with #semaglutide with respect to reduction in #bodyweight and #waistcircumference at #week72. https://t.co/SAbSMcEWLc https://t.co/5WGcDYLsHn
Full text links @NEJM Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/yzoE0XWOF8
Acceso
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/CnpXxIcpBS
RT @docramiro: Tirzepatida vs. Semaglutida Referencia: DOI: 10.1056/NEJMoa2416394 @NEJM https://t.co/jEOz4DhwqP
@FrailSkeleton https://t.co/YmKVOc68r6
今日話題になったGLP-1作動薬の比較試験（チルゼパチドvsセマグルチド）。 https://t.co/v1FOkuJFw0
RT @docramiro: Tirzepatida vs. Semaglutida Referencia: DOI: 10.1056/NEJMoa2416394 @NEJM https://t.co/jEOz4DhwqP
RT @jvillacastin: Mounjaru contra Ozempic para perder peso en personas con sobrepeso no diabéticos. Quien crees que gana? Al año y medio…..…
Tirzepatide significantly outperformed semaglutide in reducing weight and waist size in obese adults without diabetes. by Aronne LJ, Horn DB (...) Dunn JP et 8 al. in N Engl J Med #MedSky
Tirzepatide significantly outperformed semaglutide in reducing weight and waist size in obese adults without diabetes. by Aronne LJ, Horn DB (...) Dunn JP et 8 al. in N Engl J Med https://t.co/fSA7e27vAM #MedX #MedResearch
RT @drbennisahmed: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Among participants with obesity but without diabe…
@unclearirony In a head to head study it actually doesn’t work as well as tirzeparide , but I hear what you are saying https://t.co/Ej2Kq8TxcT
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @FarmaMadridAP: (NEJM) Tirzepatida en comparación con semaglutida para el Ttº de la obesidad. EC abierto SURMOUNT-5 https://t.co/fNFeXqe…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
Tirzepatide (15 mg) produces more weight loss than semaglutide (2.4 mg) when compared at their respective maximum tolerated doses 72-week study of 751 people with obesity but not diabetes Side effects were mild-to-moderate & transient https://t.co/WP8bi8Yq4k
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
توییت 8: نتیجهگیری تیرزپاتید تو کاهش وزن و متابولیسم از سماگلوتید جلو زد!
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @FarmaMadridAP: (NEJM) Tirzepatida en comparación con semaglutida para el Ttº de la obesidad. EC abierto SURMOUNT-5 https://t.co/fNFeXqe…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @drbennisahmed: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Among participants with obesity but without diabe…
(NEJM) Tirzepatida en comparación con semaglutida para el Ttº de la obesidad. EC abierto SURMOUNT-5 https://t.co/fNFeXqepqv
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
【DrゆみのWeekly Journal Scan】 ＊肥満患者におけるチルゼパチドとセマグルチドの有効性比較 from NEJM＊ https://t.co/QhIdLEn45B 非糖尿病の肥満成人751例を1対1で無作為化し、最大耐量チルゼパチド10/15 mg群とセマグルチド1.7/2.4
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/mDYfCO3Bqy Editorial: Semaglutide and Tirzepatide to Treat Obesity https://t.co/2lenpsGjiI #Endocrinology https://t.co/wu0bFnRiYJ
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @drbennisahmed: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Among participants with obesity but without diabe…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/Cc6XARMo0b
Compelling data for Tirzepatide > Semaglutide 20% weight loss!! @NEJM https://t.co/aGIENgaQ0B
SURMOUNT-5 (NEJM 2025): Tirzepatide vs Semaglutide in Obesity Tirzepatide led to: ✅ −20.2% body weight (~−22.8 kg) ✅ −18.4 cm waist ✅ 64.6% ≥15% weight loss (vs 40.1%) ✅ 31.6% ≥25% loss (vs 16.4%)
In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference. Full trial results and Research Summary: nej.md/44ZeMPz #MedSky #EndoSky
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @drbennisahmed: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Among participants with obesity but without diabe…
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72 https://t.co/T60ck2LD36
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
RT @NEJM: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide i…
In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference. Full trial results and Research Summary: https://t.co/mDYfCO3Bqy https://t.co/17HHbfakBJ
In 72 weeks, #tirzepatide helped people lose ~20% body weight and 18 cm waistline - outpacing #semaglutide’s ~14% and 13 cm. Same mild side effects.
【肥満症治療薬の一騎打ち⚖️】 NEJMから, 非糖尿病性肥満に対するTirzepatideとSemaglutideの比較試験 週1回皮下注のTirzepatideはSemaglutideに比べ, 体重と腹囲の減少効果が有意に高かった. 72週後の平均体重減少率(-20.2% vs -13.7%) BMI中央値は39
#Tirzepatide as Compared with #Semaglutide for the Treatment of #Obesity https://t.co/iYFKtIuS6V
減量効果はセマグルチドよりチルゼパチドの方が高い。 Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/MuQMapDlaQ
RT @Nigelj08223326: https://t.co/UpBYJ6lRPM @AskDrShashank @ParagSinghal09 @AmeliaCookDSN @juniorjuri In participants with obesity witho…
RT @Nigelj08223326: https://t.co/UpBYJ6lRPM @AskDrShashank @ParagSinghal09 @AmeliaCookDSN @juniorjuri In participants with obesity witho…
https://t.co/UpBYJ6lRPM @AskDrShashank @ParagSinghal09 @AmeliaCookDSN @juniorjuri In participants with obesity without diabetes
Among participants with #obesity but without #diabetes, #treatment with #tirzepatide was superior to treatment with #semaglutide with respect to reduction in #bodyweight and #waistcircumference at #week72 https://t.co/buJHoK4nAE
RT @NEJM: New in the July 3, 2025, issue of NEJM: Exercise after Chemotherapy for Colon Cancer (CHALLENGE phase 3 trial) https://t.co/uz…
New in the July 3, 2025, issue of NEJM: Exercise after Chemotherapy for Colon Cancer (CHALLENGE phase 3 trial) https://t.co/uz69rdc01o Tirzepatide vs. Semaglutide for Obesity (SURMOUNT-5 phase 3b trial) https://t.co/mDYfCO3Bqy Pembrolizumab in Head and Neck Cancer https://t.co/ptsxD9hQiy
"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." Étude SURMOUNT-5. Publiée ce jour dans le @nejm.org #MedSky #EndoSky www.nejm.org/doi/full/10....
RT @richardhirschs1: https://t.co/5gL4o1JyAR
Mounjaru contra Ozempic para perder peso en personas con sobrepeso no diabéticos. Quien crees que gana? Al año y medio….. https://t.co/rRzdqsrsRR
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/rb0TWTupKx
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/KQGJkfOhKa
In this phase 3b, open-label, randomized, controlled trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference @NEJM @ljaronnev https://t.co/mVRGJcFt2B https://t.co/FP0d0ml1pB
https://t.co/5gL4o1JyAR
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/psAXf5ketA
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @drkeithsiau: Data from the head-to-head SURMOUNT trial in @NEJM https://t.co/dsrCuCTyZs https://t.co/Y6CGWB6Fle
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @BankSongsak: สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
สรุปคร่าวๆ Semaglutide vs Tirzepatide อ่านเพิ่มได้ที่ https://t.co/ZClNDiBnLh https://t.co/ctiyNXOwp3
RT @docramiro: Tirzepatida vs. Semaglutida Referencia: DOI: 10.1056/NEJMoa2416394 @NEJM https://t.co/jEOz4DhwqP
New #Obesity Publication → Head-to-Head Study Comparing Dual and Single Incretin Receptor Agonists in Obesity Treatment Click here to read the full study: https://t.co/o79sPe155o #obesityresearch #obesitymedicine https://t.co/mgvklNUK3O
New #Obesity Publication → Head-to-Head Study Comparing Dual and Single Incretin Receptor Agonists in Obesity Treatment Click here to read the full study: https://t.co/o79sPe1CUW #obesityresearch #obesitymedicine
RT @DrDamluji: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: @NEJM
@Carmelo_Tiberio @Ash_Shoamanesh Tirzapetide drops BP around 10mmHg in obese patients - so should reduce ICH at maximally tolerated doses by 30-50%… https://t.co/Go46GgqEiO
RT @ValleAlfonso:
RT @A_May_MD: Fitting day for the $LLY tirzepatide versus $NVO semaglutide head to head study to be released in the NEJM. $LLY delivered a…
RT @ValleAlfonso:
RT @ValleAlfonso:
RT @docwas: Tirzepatide superior as Compared with Semaglutide for the Treatment of Obesity | SURMONT 5 https://t.co/O1HaR0CZ9G
New Obesity Publication → Incretin receptor agonist as compared with another incretin receptor agonist for the treatment of Obesity Click here to read the full study: https://t.co/o79sPe155o #obesityresearch #obesitymedicine #obesity
@Pharma_Pro Obesity and waist circumference are pretty strongly tied to poor outcomes. We have a 751 patient study that shows Tirzepatide is superior https://t.co/cyrxedXAzP https://t.co/E2hoy96FiI
論文リンク https://t.co/WPC2i4T308
RT @ObesitySeen: SURMOUNT-5: RCT comparativo tirzepatida vs semaglutida 2.4 mg en obesidad.
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @ObesitySeen: SURMOUNT-5: RCT comparativo tirzepatida vs semaglutida 2.4 mg en obesidad.
RT @ObesitySeen: SURMOUNT-5: RCT comparativo tirzepatida vs semaglutida 2.4 mg en obesidad.
RT @ObesitySeen: SURMOUNT-5: RCT comparativo tirzepatida vs semaglutida 2.4 mg en obesidad.
RT @ObesitySeen: SURMOUNT-5: RCT comparativo tirzepatida vs semaglutida 2.4 mg en obesidad.
RT @ObesitySeen: SURMOUNT-5: RCT comparativo tirzepatida vs semaglutida 2.4 mg en obesidad.
RT @ObesitySeen: SURMOUNT-5: RCT comparativo tirzepatida vs semaglutida 2.4 mg en obesidad.
RT @ObesitySeen: SURMOUNT-5: RCT comparativo tirzepatida vs semaglutida 2.4 mg en obesidad.
RT @ObesitySeen: SURMOUNT-5: RCT comparativo tirzepatida vs semaglutida 2.4 mg en obesidad.
SURMOUNT-5: RCT comparativo tirzepatida vs semaglutida 2.4 mg en obesidad.
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
Tirzepatida comparada con semaglutida para el tratamiento de la obesidad https://t.co/LuL0d5Zt7Z PMID 40353578
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine www.nejm.org/doi/full/10....
RT @MarkusAtHome: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity by Drs. @ljaronne, Dunn et al. https://t.co/SL0VCC…
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity by Drs. Aronne, Dunn et al. www.nejm.org/doi/full/10.... Treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity by Drs. @ljaronne, Dunn et al. https://t.co/SL0VCCId2l Treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. https://t.co/kR0Ir53T9w
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/ovf7Sy7ViK
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/JXL0FaFtq9
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Standard dose schedule for each compound Slightly more GI side effects with sema; greater weight loss and reduction in waist circumference with tirze https://t.co/WP8bi8Yq4k https://t.co/FfuaRNTQRB
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine. https://t.co/tNdJHU9Qux
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine Tirzepatide was superior to Semaglutide weight loss percentage over 72 weeks. https://t.co/2xWri7P18r
結果 Tirzepatide as Compared with Semaglutide for the Treatment of Obesity https://t.co/lPy6QfyluJ
Tirzepatide significantly outperformed semaglutide in reducing obesity after 72 weeks in non-diabetic adults. by Aronne LJ, Horn DB (...) Dunn JP et 8 al. in N Engl J Med #MedSky
Tirzepatide significantly outperformed semaglutide in reducing obesity after 72 weeks in non-diabetic adults. by Aronne LJ, Horn DB (...) Dunn JP et 8 al. in N Engl J Med https://t.co/fSA7e27vAM #MedX #MedResearch
P:2型糖尿病なしの肥満成人 E:トリゼパチド（マンジェロ）週1投与(10/15mg) C:セマグルチド週1投与(1.7/2.4mg) O:72週時の体重の百分率変化 トリゼパチド群で−20.2%（95%CI −21.4〜−19.1） セマグルチド群で−13.7%（−14.9〜−12.6） トリゼパチド群の方が有意に減った https://t.co/JikLYLT6Y4
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. https://t.co/EZXB83FwEP
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. https://t.co/EZXB83FwEP
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/BcsgKNX4ud
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine www.nejm.org/doi/10.1056/...
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/AYOrKhnTIu
RT @DrDamluji: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: @NEJM
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. https://t.co/EZXB83FwEP
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine https://t.co/hFdFKqmehL
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
RT @DrDamluji: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: @NEJM
RT @SeguraCardio:
RT @DrDamluji: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: @NEJM
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. https://t.co/EZXB83FwEP
RT @NEJM: Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/…
New research shows tirzepatide helps adults with obesity lose more weight than semaglutide over 72 weeks!
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. https://t.co/EZXB83FwEP
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. https://t.co/EZXB83FwEP
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine www.nejm.org/doi/full/10....
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. https://t.co/EZXB83FwEP
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity www.nejm.org/doi/full/10....
Link to original study in NEJM (free of registered)
Just published @nejm.org A randomized trial of Semaglutide (Ozempic) vs Tirzepatide (Mounjaro, Zepbound) at max doses demonstrates superiority of the latter for weight loss www.nejm.org/doi/full/10.1056/NEJMoa2416394
KP
JG
H
A
AL